Key result
Adjuvant chemotherapy following amputation increased 5-year disease-free survival to 34.0% compared to 7.0% with surgery alone in patients with local osteogenic sarcoma.
Why the study?
Does adjuvant chemotherapy improve disease-free survival in patients with osteogenic sarcoma compared to surgery alone?
Cohort (n=313)
No
Does adjuvant chemotherapy improve disease-free survival in patients with osteogenic sarcoma compared to surgery alone?
Adjuvant chemotherapy significantly improves disease-free survival in patients with osteogenic sarcoma compared to surgery alone.
Answers are grounded in this paper and cite their sources.
Adjuvant chemotherapy may improve DFS after amputation; leaves open need for randomized confirmation in osteogenic sarcoma.
The experience in the management of 246 patients with local osteogenic sarcoma and 67 patients with pulmonary metastases in the All-Union Oncologic Research Center, AMS USSR, is presented here. All the patients underwent surgery, but starting in 1974, various modalities of adjuvant chemotherapy (not randomized) were applied in addition. In the surgery alone group, prognosis was very poor: only 7.0% of patients survived free of disease 5 years from the primary tumor treatment. Adjuvant chemotherapy (adriamycin + vincristine + melphalan + cyclophosphamide) following amputations increased this rate to 34.0%; combining segmental resections of an affected bone with preoperative intraarterial adriamycin infusion and radiation (36 Gy) increased the rate to 35.5%. In patients with grade 4 tumor damage (tumor cells are not found upon examination of a large number of sections), the rate increased to 57.9% (P less than .05). Another regimen of adjuvant chemotherapy (platidiam or cisplatin + adriamycin + cyclophosphamide) gives a chance to 78.8% of patients to survive 1 year free of metastases. The same chemotherapy regimen enables us to achieve an objective effect in 30.8% of patients with pulmonary metastases, and its combination with surgical metastasis ablation makes it possible to obtain a complete remission, lasting from 2 to 46 months (average 13.9 months). Toxic manifestations of the chemotherapy regimens considered are moderate. Prognosis in adjuvant chemotherapy is related to age, tumor site, its local dissemination, and morphologic type of osteogenic sarcoma.
No takes yet. Share an insight, caveat, or question.
Трапезников et al. (1986) conducted a cohort in Osteogenic sarcoma (n=313). Adjuvant chemotherapy vs. Surgery alone was evaluated on 5-year disease-free survival. Adjuvant chemotherapy following amputation increased 5-year disease-free survival to 34.0% compared to 7.0% with surgery alone in patients with local osteogenic sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: